Departing United States senators Jeanne Shaheen and Susan Collins are mounting a final legislative effort to establish a mandatory insulin price cap for individuals covered by commercial health insurance. Lawmakers on Capitol Hill are considering this bipartisan proposal as part of broader end-of-year legislative packages before the current congressional session concludes.
Senator Jeanne Shaheen of New Hampshire is retiring from Congress, while Senator Susan Collins of Maine lost her re-election bid to Democrat Troy Jackson, meaning both lawmakers are leaving office at the end of the year. Their proposed measure features twenty-eight co-sponsors divided evenly between the Democratic and Republican parties in the Senate.
The legislation would restrict out-of-pocket expenses for the medication to $35 for people with commercial insurance. This provision mirrors a similar rule established for seniors enrolled in Medicare through the Inflation Reduction Act signed by former President Biden in 2022. Additionally, the proposal establishes a pilot program across ten states aimed at limiting costs for uninsured individuals.
The Senate Committee on Health, Education, Labor and Pensions advanced the bill during July, bringing the measure closer to a full chamber vote than it has ever been previously. Members of Congress have debated various caps on medication expenses for years, but prior efforts stalled due to strong Republican opposition against government intervention in pricing.
Senator Shaheen pointed to recent midterm election outcomes as evidence that the public expects elected officials to approve policies reducing financial burdens. In a public statement issued this week, she emphasized that the legislation offers a direct bipartisan pathway to deliver financial relief to households by limiting monthly expenses for the medication.
Legislative Pathways and Prior Reforms
Congressional leaders view attaching the measure to a year-end spending bill as the most viable path forward for enactment. Alternatively, lawmakers could incorporate the proposal into the must-pass defense policy and spending authorization legislation before the session ends.
The previous policy implemented under former President Biden successfully capped expenses at $35 per month exclusively for older adults on Medicare. That earlier healthcare package cleared Congress entirely without support from Republican legislators.
Although numerous major pharmaceutical manufacturers subsequently lowered their catalog prices voluntarily following that federal action, both senators argue that voluntary reductions remain inadequate for patients. High medication expenses continue acting as a significant barrier to proper medical care for numerous residents across the United States.
Advocacy and Patient Impact
Implementing a monthly ceiling on patient cost sharing lowers immediate out-of-pocket expenses and expands treatment accessibility, though the policy does not directly alter the underlying wholesale cost charged by manufacturers. Advocacy groups, including the American Diabetes Association and the National Kidney Foundation, dispatched formal letters last week to the White House and congressional leadership from both parties, urging immediate enactment of the bill.